GlassScriptPhysician profile
Jennifer Jerome
NPI 1134661531
$8,809.29
in general payments reported to CMS, 2019-2025
35 companies · $2,599 in 2025
The $2,599 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,216 · 2022: $765 · 2023: $1,356 · 2024: $1,873 · 2025: $2,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,587 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,587.10 |
| Education | $240.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,238.78 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $710.87 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $579.76 | 2021-2025 | Airsupra, Bevespi Aerosphere, Breztri |
| Axsome Therapeutics, INC. | $546.58 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $507.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.14 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $373.61 | 2021-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $314.68 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $231.38 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.34 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $199.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $169.54 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Optinose US, INC. | $162.78 | 2023-2025 | |
| Pfizer INC. | $145.02 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $144.86 | 2024-2025 | Rexulti, Abilify Maintena |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $133.79 | 2024-2025 | Veozah |
| Lundbeck LLC | $92.03 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $78.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $65.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $59.46 | 2025 | Spravato |
| Bausch Health US, LLC | $57.63 | 2021-2023 | Wellbutrin, Aplenzin |
| Sanofi-Aventis U.S. LLC | $57.22 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.39 | 2022 | |
| Qol Medical, LLC | $45.16 | 2021 | |
| Impel Pharmaceuticals INC. | $44.80 | 2023 | Trudhesa |
| Phathom Pharmaceuticals, INC. | $30.70 | 2024-2025 | Voquezna |
| Corium, LLC | $22.62 | 2025 | Azstarys |
| Xeris Pharmaceuticals, INC. | $21.58 | 2025 | Recorlev |
| Paratek Pharmaceuticals, INC. | $20.46 | 2025 | Xhance, Nuzyra |
| Abbott Laboratories | $19.66 | 2021 | |
| Tms Neurohealth Centers INC. | $19.53 | 2025 | Tms Neurohealth Centers INC. |
| Mylan Specialty L.P. | $17.60 | 2021 | |
| Ardelyx, INC. | $14.35 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.74 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jerome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.